Summary In a phase I study of weekly administered cisplatin combined with oral etoposide, we observed a partial response in 4 out of 11 patients with metastatic colorectal cancer. Subsequently, we performed a phase II study to investigate the activity of this combination as first-line treatment in this disease. Fourteen patients with metastatic colorectal cancer were enrolled in this study. The poor prognosis for numerous patients with metastatic colorectal cancer is an incentive for oncologists to explore new treatments for this disease. The combination of fluorouracil with leucovorin is nowadays the more or less accepted standard treatment, but the optimum treatment schedule still has to be defined (Moertel, 1994) . Cisplatin as a single agent at standard doses is inactive in colorectal cancer (DeSimone et al., 1986) but in combination with fluorouracil a modest activity has been reported (Posner et al., 1987; LoRuss et al., 1989; Kemeny et al., 1990) . Etoposide as a single agent given intravenously is inactive in colorectal cancer (Perry et al., 1976; Douglass et al., 1979) . As colorectal tumours are in general slow growing, a more prolonged administration of cytotoxic drugs may be advantageous. Oral etoposide can be given over a long period of time with acceptable toxicity (Greco et al., 1990) . Activity of oral etoposide has been shown in small-cell and non-small-cell lung cancer, germ cell tumours and breast cancer. In a phase I study of weekly cisplatin combined with oral etoposide a partial response was observed in 4 out of 11 patients with metastatic colorectal cancer, most of them pretreated with fluorouracil (Planting et al., 1995 During treatment patients had weekly physical examinations and assessment of toxicity, weekly full blood counts and estimation of electrolytes, calcium and magnesium and creatinine clearance. Neurological examination including VPT was repeated after the cisplatin treatment period. Response to treatment was assessed 2 weeks after the last cisplatin administration. The standard WHO criteria were used for evaluation of response and toxicity (WHO, 1979).
The poor prognosis for numerous patients with metastatic colorectal cancer is an incentive for oncologists to explore new treatments for this disease. The combination of fluorouracil with leucovorin is nowadays the more or less accepted standard treatment, but the optimum treatment schedule still has to be defined (Moertel, 1994) . Cisplatin as a single agent at standard doses is inactive in colorectal cancer (DeSimone et al., 1986) but in combination with fluorouracil a modest activity has been reported (Posner et al., 1987; LoRuss et al., 1989; Kemeny et al., 1990) . Etoposide as a single agent given intravenously is inactive in colorectal cancer (Perry et al., 1976; Douglass et al., 1979) . As colorectal tumours are in general slow growing, a more prolonged administration of cytotoxic drugs may be advantageous. Oral etoposide can be given over a long period of time with acceptable toxicity (Greco et al., 1990) . Activity of oral etoposide has been shown in small-cell and non-small-cell lung cancer, germ cell tumours and breast cancer. In a phase I study of weekly cisplatin combined with oral etoposide a partial response was observed in 4 out of 11 patients with metastatic colorectal cancer, most of them pretreated with fluorouracil (Planting et al., 1995 (Hilkens et al., 1994) . Six patients reported tinnitus as a side-effect. There were no patients with nephrotoxicity.
Discussion
The combination of fluorouracil with leucovorin is at this moment accepted as 'standard' treatment in metastatic colorectal cancer with an overall response rate of 23%. Various schedules have been explored with similar response rates. The combination of 5 day low-dose leucovorin with moderate dose fluorouracil every 4-5 weeks is considered the least toxic and most 'cost-effective ' (Moertel, 1994) .
In this phase II study we explored the value of frequently administered high-dose cisplatin combined with oral etopo- (Loehrer et al., 1988; Labianca et al., 1988; Scheithauer et al., 1994) . A prospective randomised trial comparing continuous fluorouracil infusion with a combination with weekly low-dose cisplatin (20 mg m-2) did not show any benefit of the combination (Lokich et al., 1991) . We therefore conclude that the combination of 5-FU plus leucovorin is still the 'poor winner' and further studies with new drugs remain essential.
